---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-052170"
form_type: "8-K"
ticker: "RYTM"
cik: "0001649904"
company_name: "RHYTHM PHARMACEUTICALS, INC."
filed_at: "2026-08-04T11:49:13+00:00"
generated_at: "2026-08-04T11:50:10.367528+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rhythm Pharma Q2 revenue $71.3M; RM-718 shows -11.6% BMI reduction in HO

## Summary
- Q2 2026 IMCIVREE revenue $71.3M, up 19% sequentially; U.S. revenue $51.0M (+38% QoQ).
- Over 400 patient start forms for IMCIVREE in acquired HO since FDA approval in March 2026.
- RM-718 Phase 2: -11.6% mean BMI reduction at 16 weeks (n=7) in acquired HO, comparable to setmelanotide.
- Net loss $(50.4)M ($(0.73)/share) vs $(48.0)M ($(0.75)/share) in Q2 2025.
- Cash $330.9M; FY 2026 Non-GAAP OpEx guidance $363M-$397M.

## SEC filing metadata
- accession: 0001628280-26-052170
- form_type: 8-K
- ticker: RYTM
- cik: 0001649904
- company_name: RHYTHM PHARMACEUTICALS, INC.
- filed_at: 2026-08-04T11:49:13+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649904/000162828026052170/0001628280-26-052170-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649904/000162828026052170/rytm-20260804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-052170
- JSON: https://secwatch.observer/filing/0001628280-26-052170.json
- Plain text: https://secwatch.observer/filing/0001628280-26-052170.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.